cadila healthcare ltd
(CDH:National Stock Exchange of India)
Sharvil P. Patel
Deputy Managing Director, Director and Member of Committee of Directors, Cadila Healthcare Limited
|Age||Total Calculated Compensation||This person is connected to 16 board members in 2 different organizations across 2 different industries.|
See Board Relationships
Dr. Sharvil P. Patel has been Deputy Managing Director of Cadila Healthcare Limited since July 27, 2007. Dr. Patel serves as Deputy Managing Director of Zydus Cadila. He has been the Chairman of Zydus Wellness Limited since July 14, 2014. He has been Non-Executive Director of Cadila Healthcare Limited since August 16, 2003. He has been a Non-Executive Director of Zydus Wellness Limited since April 27, 2009. He serves on The Board of The following Public Limited Companies: ...
Zydus TowerPhone: 91 79 2686 8100
Ahmedabad, Gujarat 380015
Fax: 91 79 2686 2365
Board Members Memberships*
Deputy Managing Director, Director and Member of Committee of Directors
Chairman, Chairman of Corporate Social Responsibility Committee, Chairman of Share Transfer Committee, Member of Committee of Directors and Member of Nomination & Remuneration Committee
University of Sunderland
Johns Hopkins School of Medicine
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Samir Uttamlal Mehta M.B.A.||Executive Vice Chairman, Managing Director, Member of Securities Transfer & Stakeholders Relationship Committee and Member of Committee of Directors|
Torrent Pharmaceuticals Ltd.
|Murtaza H. Khorakiwala||Managing Director, Executive Director, Member of Share Allotment Committee and Member of Credit Facilities Committee|
|Subhanu Saxena||Managing Director, Global Chief Executive Officer and Director|
|Glenn Mario Saldanha||Chairman of The Board, Chief Executive Officer, Managing Director, Member of Nomination & Remuneration Committee and Member of Shareholders/Investors Grievance Committee|
Glenmark Pharmaceuticals Ltd.
|57.1M||Compensation as of Fiscal Year 2015.|